Location
Sydnor Performance Hall, Schewel Hall
Access Type
Campus Access Only
Presentation Type
Oral presentation
Entry Number
206
Start Date
4-16-2026 11:00 AM
End Date
4-16-2026 11:15 AM
School
School of Liberal Arts and Sciences
Department
Biological Science
Keywords
Breast cancer, Infiltrating lobular carcinoma, Peritoneal carcinomatosis, Metastasis
Abstract
Breast cancer is the second leading cause of cancer death among women in the United States. While most metastases of breast cancer include the liver, lungs, bones, or brain, metastasis to the peritoneum is very rare and difficult to treat. Patients with peritoneal metastases had the worst overall survival compared to other breast cancer metastases. Infiltrating lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer, and it tends to spread to the gastrointestinal or peritoneal regions of the body. About 70% of patients with cancer spread to the peritoneum also experience ascites. Some symptoms of the spread include: abdominal pain, bloating, melena, GI hemorrhage, bowel obstruction, nausea and vomiting, early satiety, dysphagia, weight loss, anemia, or fatigue. There are limited treatment options for peritoneal carcinomatosis, but some include Cytoreduction Surgery (CRS), which is then followed by Hyperthermic Intraperitoneal Chemotherapy or Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). This scoping review examines patient risk factors, histologic subtypes, presenting symptoms, and available treatments for peritoneal carcinomatosis secondary to breast cancer.
Primary Faculty Mentor(s)
Dr. Allison Jablonski
Primary Faculty Mentor(s) Department
Biology
Additional Faculty Mentor(s)
Dr. Kari Benson Dr. Freier
Rights Statement
The right to download or print any portion of this material is granted by the copyright owner only for personal or educational use. The author/creator retains all proprietary rights, including copyright ownership. Any editing, other reproduction or other use of this material by any means requires the express written permission of the copyright owner. Except as provided above, or for any other use that is allowed by fair use (Title 17, §107 U.S.C.), you may not reproduce, republish, post, transmit or distribute any material from this web site in any physical or digital form without the permission of the copyright owner of the material.
Scoping Review of Metastatic Breast Cancer Patients with Peritoneal Carcinomatosis
Sydnor Performance Hall, Schewel Hall
Breast cancer is the second leading cause of cancer death among women in the United States. While most metastases of breast cancer include the liver, lungs, bones, or brain, metastasis to the peritoneum is very rare and difficult to treat. Patients with peritoneal metastases had the worst overall survival compared to other breast cancer metastases. Infiltrating lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer, and it tends to spread to the gastrointestinal or peritoneal regions of the body. About 70% of patients with cancer spread to the peritoneum also experience ascites. Some symptoms of the spread include: abdominal pain, bloating, melena, GI hemorrhage, bowel obstruction, nausea and vomiting, early satiety, dysphagia, weight loss, anemia, or fatigue. There are limited treatment options for peritoneal carcinomatosis, but some include Cytoreduction Surgery (CRS), which is then followed by Hyperthermic Intraperitoneal Chemotherapy or Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). This scoping review examines patient risk factors, histologic subtypes, presenting symptoms, and available treatments for peritoneal carcinomatosis secondary to breast cancer.